Premium
Clinical significance of serum Dkk‐3 in patients with gynecological cancer
Author(s) -
Jiang Tao,
Huang Ling,
Wang Shizhuo,
Zhang Shulan
Publication year - 2010
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2010.01234.x
Subject(s) - medicine , ovarian cancer , endometrial cancer , cervical cancer , cancer , clinical significance , oncology , gastroenterology
Aim: The expression of Dkk‐3, as a number of the Dkk family was different in different cancer. Because Dkk‐3 encodes a secreted protein, we investigated whether the Dkk‐3 protein is secreted into the sera of patients with gynecological cancer. Material & Methods: The levels of Dkk‐3 protein were assessed by enzyme‐linked immunosorbent assay in the sera of 104 patients with gynecological cancer: 36 with ovarian, 40 with cervical and 28 with endometrial cancers. Results: The serum levels of Dkk‐3 protein in patients with ovarian cancer [25.54 (7.99) pg/mL] was lower than in normal individuals [42.08 (14.89) pg/mL] ( P = 0.000). But serum levels of Dkk‐3 protein in patients with cervical [166.39 (300.68) pg/mL] ( P = 0.013) and endometrial cancers [73.64 (23.36) pg/mL] ( P = 0.000) were higher than in normal individuals. The serum levels of Dkk‐3 protein were associated with clinical stage in patients with cervical and endometrial cancers. In patients with ovarian cancer, the serum levels of Dkk‐3 protein were associated with lymphatic metastasis. In patients with cervical cancer, the serum levels of Dkk‐3 protein were associated with tumor diameters. Conclusion: Dkk‐3 protein detection using enzyme‐linked immunosorbent assay as molecular markers can contribute to detection and diagnosis of gynecological cancer, especially for ovarian cancer and endometrial cancer.